Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes : UKPDS 40.
To estimate the economic efficiency of tight blood pressure control, with angiotensin converting enzyme inhibitors or bêta blockers, compared with less tight control in hypertensive patients with type 2 diabetes.
Cost effectiveness analysis incorporating within trial analysis and estimation of impact on life expectancy through use of the within trial hazards of reaching a defined clinical end point Use of resources driven by trial protocol and use of resources in standard clinical practice were both considered.
20 hospital based clinics in England, Scotland, and Northern Ireland.
1148 hypertensive patients with type 2 diabetes from UK prospective diabetes study randomised to tight control of blood pressure (n=758) or less tight control (n=390).
Main outcome measure
Cost effectiveness ratios based on (a) use of healthcare resources associated with tight control and less tight control and treatment of complications and (b) within trial time free from diabetes related end points, and life years gained.
Based on use of resources driven by trial protocol, the incremental cost effectiveness of tight control compared with less tight control was cost saving.
Based on use of resources in standard clinical practice, incremental cost per extra year free from end points amounted to £1049 (costs and effects discounted at 6% per year) and £434 (costs discounted at 6% per year and effects not discounted). (...)
Mots-clés Pascal : Diabète non insulinodépendant, Antihypertenseur, Inhibiteur angiotensin converting enzyme, Hypertension artérielle, Traitement, Chimiothérapie, Bloquant bêta-adrénergique, Analyse coût efficacité, Complication, Survie, Economie santé, Homme, Endocrinopathie, Appareil circulatoire pathologie
Mots-clés Pascal anglais : Non insulin dependent diabetes, Antihypertensive agent, ACE inhibitor, Hypertension, Treatment, Chemotherapy, Beta blocking agent, Cost efficiency analysis, Complication, Survival, Health economy, Human, Endocrinopathy, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0432323
Code Inist : 002B02F05. Création : 25/01/1999.